Rifamycin sodium salt

CAS No. 14897-39-3

Rifamycin sodium salt ( —— )

Catalog No. M19784 CAS No. 14897-39-3

Rifamycin is an antibiotic that inhibits bacterial DNA-dependent RNA polymerase. It is effective against Gram-positive bacteria.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 35 In Stock
100MG 50 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Rifamycin sodium salt
  • Note
    Research use only not for human use.
  • Brief Description
    Rifamycin is an antibiotic that inhibits bacterial DNA-dependent RNA polymerase. It is effective against Gram-positive bacteria.
  • Description
    Rifamycin is an antibiotic that inhibits bacterial DNA-dependent RNA polymerase. It is effective against Gram-positive bacteria.
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Antibacterial
  • Recptor
    Antibacterial
  • Research Area
    ——
  • Indication
    Mycobacterium tuberculosis

Chemical Information

  • CAS Number
    14897-39-3
  • Formula Weight
    719.75
  • Molecular Formula
    C37H46NNaO12
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 90 mg/mL
  • SMILES
    [Na+].CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)cc(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c([O-])c2c(O)c3C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Riva S et al. Rifamycins: a general view. Annu Rev Microbiol. 1972;26:199-224.
molnova catalog
related products
  • BEC HCl

    BEC HCl is a competitive arginase inhibitor, which bind slowly. Ki of BEC HCl is 0.31 μM (pH7.5) for Arginase II, and is 0.4-0.6 μM for rat Arginase I.

  • Phenylmercuric aceta...

    A phenyl mercury compound used mainly as a fungicide. Has also been used as a herbicide slimicide and bacteriocide.

  • Capreomycin sulfate

    A peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for MDR-tuberculosis.